• ABL Diagnostics filed a bid on Sept. 11, 2026 to acquire IntegraGen’s business operations and assets.
• IntegraGen focuses on genomic analysis of nucleic acids, with work in oncology and rare genetic diseases.
• The proposed deal remains subject to a decision by the Commercial Court of Évry, with no certainty ABL Diagnostics will be selected.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260911655644) on September 11, 2026, and is solely responsible for the information contained therein.